Engineered GM1 Intersects Between Mitochondrial and Synaptic Pathways to Ameliorate ALS Pathology (Adv. Sci. 20/2026)

Therapy for Amyotrophic Lateral Sclerosis A nanoliposome-based formulation of the neuroprotective ganglioside GM1, termed Talineuren (TLN), is presented as a promising therapeutic approach for amyotrophic lateral sclerosis (ALS). TLN is designed to enhance bioavailability and deliver potent neuroprotection, through normalization of mitochondrial and ER functions, reduction of inflammation, and restoration of proteostasis. These coordinated actions help preserve synaptic integrity and ameliorate disease-associated dysfunction, highlighting TLN as a compelling candidate for ALS treatment. More details can be found in the Research Article by Federica Pilotto, Smita Saxena, and co-workers (DOI: 10.1002/advs.202514128). Image created in BioRender.com.